Kan Chen

Kan Chen is a partner at Qiming Venture Partners, where he was promoted in January 2022 and has since taken on an expanded leadership role alongside fellow managing partners Hu Xubo and Zhou Zhifeng as the firm enters its post-founding generation . His investment focus is healthcare, particularly innovative drug development and global expansion—an area where he speaks with authority given his scientific background .

Before venture capital, Chen spent his early career as a senior scientist at Johnson & Johnson working on oncology drug R&D, and prior to that served as a team leader at Hengrui Medicine, one of China's largest pharmaceutical companies . His academic path ran from Fudan University undergraduate through postdoctoral training at Harvard Medical School .

At Qiming, Chen has been vocal about the firm's cross-border business development track record: between 2022 and 2024, its portfolio companies completed 19 cross-border BD transactions totaling over $8.5 billion, with 47 healthcare investments in 2023 alone . His positioning reflects Qiming's bet that scientific depth—rather than pure financial training—defines the next generation of China healthcare investors.